Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 17/20 | 0.80 |
| ▸ | JAK3 | P52333 | 7/20 | 0.69 |
| ▸ | TYK2 | P29597 | 4/20 | 0.69 |
| ▸ | JAK1 | P23458 | 4/20 | 0.69 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.66 |
| ▸ | NCOR1 | O75376 | 1/20 | 0.66 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.66 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.66 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.66 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.66 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.64 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.64 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2875288 | 0.89 | JAK2 (1.00) | JAK2JAK3TYK2JAK1HDAC3 | |
| SCHEMBL13590716 | 0.89 | JAK2 (1.00) | JAK2JAK3TYK2JAK1HDAC3 | |
| Hydrochloric Acid SCHEMBL30221695 | 0.87 | JAK2 (0.96) | JAK2JAK3TYK2JAK1HDAC3 | |
| SCHEMBL13724670 | 0.87 | JAK2 (0.69) | JAK2JAK3TYK2JAK1HDAC3 | |
| SCHEMBL12801112 | 0.85 | JAK2 (1.00) | JAK2JAK3TYK2JAK1MAPK8 | |
| SCHEMBL13725012 | 0.85 | JAK2 (0.67) | JAK2JAK3TYK2JAK1HDAC3 | |
| SCHEMBL4379023 | 0.84 | JAK2 (0.80) | JAK2JAK3TYK2JAK1MAPK8 | |
| SCHEMBL2868626 | 0.84 | JAK2 (1.00) | JAK2JAK3TYK2JAK1HDAC1 | |
| SCHEMBL17287423 | 0.83 | JAK2 (0.75) | JAK2JAK3TYK2JAK1HDAC3 | |
| SCHEMBL12274500 | 0.83 | CAMK2D (0.81) | JAK2JAK3TYK2JAK1MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150352108-A1 | AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBK1 AND/OR IKK EPSILON | ALZHEIMER'S INSTITUTE OF AMERICA (US) | 2015-12-10 | — | — | US | disclosed |
| US-20150352108-A1 | AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBK1 AND/OR IKK EPSILON | ALZHEIMER'S INSTITUTE OF AMERICA (US) | 2015-12-10 | — | — | US | disclosed |
| US-8486941-B2 | Phenyl amino pyrimidine compounds and uses thereof | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2013-07-16 | — | — | US | disclosed |
| US-20120238540-A1 | AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF IKK EPSILON AND/OR TBK1 | MYREXIS, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| US-20120238540-A1 | AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF IKK EPSILON AND/OR TBK1 | MYREXIS, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| WO-2011046970-A1 | AMINO - PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBKL AND/OR IKK EPSILON | MYREXIS, INC. (US) | 2011-04-21 | — | — | WO | disclosed |
| US-20100197671-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE LLC | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197671-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | JAK2, JAK1, JAK3 | JAK2 1/4885JAK3 3/4885TYK2 6/4885 |
| US-20150352108-A1 | AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBK1 AND/OR IKK EPSILON | TBK1, NFKBIA, CHUK | JAK2 1160/4885JAK3 476/4885TYK2 996/4885 |
| US-20120238540-A1 | AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF IKK EPSILON AND/OR TBK1 | TBK1, NFKBIA, IKBKB | JAK2 458/4885JAK3 197/4885TYK2 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.